Syncom Formulations (India) Ltd.

15.24 -0.13 ▼-0.9%

23 February 2024, 04:01:00 PM
Volume: 195,421

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.sfil.in
Market Cap 1,425.04 Cr.
Enterprise Value(EV) 1,505.13 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 0.28 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 54.01 Trailing Twelve Months Ending 2023-12
Industry PE 41.88 Trailing Twelve Months Ending 2023-12
Book Value / Share 2.95 Trailing Twelve Months Ending 2023-12
Price to Book Value 5.14 Calculated using Price: 15.16
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 94.00 Cr. 940,000,000 Shares
FaceValue 1
About Syncom Formulations (India) Ltd.
Syncom Formulations (India) Ltd was originally incorporated as Syncom Formulations (India) Private Limited in the state of Maharashtra on June 21, 1988 under the Companies Act, 1956. Further the status of company was changed to public limited company and thereby name of company changed to Syncom Formulations (India) Limited and a fresh certificate of change of name obtained on July 9, 1992.

Syncom Formulations (India) Ltd. Delivery

Delivered Qty
Traded Qty

Syncom Formulations (India) Ltd. Performance

1 Day
-0.85%
1 Week
-1.10%
1 Month
-3.97%
3 Month
+38.04%
6 Month
+72.40%
1 Year
+129.52%
2 Year
+50.15%
5 Year
+1471.13%
10 Year
+177.09%

Syncom Formulations (India) Ltd. Fundamental Ratios

7 years 2013-03 2014-03 2015-03 2016-03 2017-03 2022-03 2023-03
Return on Equity (%) 6.45 10.19 9.99 9.91 9.32 11.83 8.48
Return on Capital Employed (%) 10 15.29 15.55 14.72 13.28 13.72 9.68
Return on Assets (%) 4.54 6.95 6.82 6.41 5.78 8.04 5.85

Syncom Formulations (India) Ltd. Balance Sheet

Particulars 8 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 88 95 100 109 117 222 256 270
Non Curr. Liab. 8 7 6 6 8 8 9 9
Curr. Liab. 29 42 37 66 59 78 113 124
Minority Int.
Equity & Liab. 124 144 143 181 184 308 378 404
Non Curr. Assets 63 66 59 89 97 168 196 213
Curr. Assets 62 78 84 92 87 140 182 191
Misc. Exp. not W/O
Total Assets 124 144 143 181 184 308 378 404

Syncom Formulations (India) Ltd. Profit and Loss

Particulars 8 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 115 151 173 184 185 220 224 250
Other Income 1 1 2 3 3 12 15 17
Total Income 116 152 175 187 188 232 239 267
Total Expenditure -104 -135 -155 -167 -168 -200 -204 -224
PBIDT 12 17 20 19 19 32 35 43
Interest -1 0 0 0 0 -2 -3 -5
Depreciation -3 -3 -3 -3 -3 -4 -5 -5
Taxation -3 -5 -6 -6 -5 -6 -7 -8
Exceptional Items -1 0 0 0 0 0
PAT 6 9 10 10 11 20 20 26
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 6 9 10 10 11 20 20 26
Adjusted EPS 0 0 0 0 0 0 0 0

Syncom Formulations (India) Ltd. Cash Flow

Particulars 7 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 6 7 0 24 14 16 11
Cash Fr. Inv. 0 -4 1 -23 -18 -27 -45
Cash Fr. Finan. -6 -1 1 -2 5 8 35
Net Change -1 2 2 -1 1 -2 1
Cash & Cash Eqvt 4 5 7 6 7 0 1

Syncom Formulations (India) Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 44.01 46.12 50.57 50.57 50.57 50.57 50.57 50.57 50.57
Public 55.99 53.88 49.43 49.43 49.43 49.43 49.43 49.43 49.43
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Syncom Formulations (India) Ltd. Announcements

Thu, 15 Feb 2024
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 read with schedule III and in compliance with Reg 47(1)(b) of SEBI(LODR) We herewith enclose newspaper advertisement published regarding financial results for the quarter ended 31.12.2023
Wed, 14 Feb 2024
Announcement Under Reg 30 (LODR)
Announcement under Reg 30 (LODR)-LAUNCING OF NEW PRODUCT
Wed, 14 Feb 2024
Submission Of The Statement Of Deviation Pursuant To Regulation 32(1) For The Quarter And Nine Months Ended On 31St December 2023 As Per SEBI (LODR) Regulations 2015.
submission of the statement of deviation for the quarter ended 31.12.2023

Syncom Formulations (India) Ltd. Technical Scans

Fri, 23 Feb 2024
High Increase in 3 Months High Increase in 3 Months
High Increase in 6 Months High Increase in 6 Months
High Increase in 1 Year High Increase in 1 Year
High Increase in 2 Years High Increase in 2 Years
High Increase in 5 Years High Increase in 5 Years

Syncom Formulations (India) Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 374,572.18 1,560.95 +0.2%
Cipla Ltd. 118,375.92 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. 107,511.08 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. 97,345.81 6,742.15 -0.4%
Divi's Laboratories Ltd. 96,748.70 3,636.05 -0.3%
Zydus Lifesciences Ltd. 93,335.34 922.10 +1.9%
Torrent Pharmaceuticals Ltd. 88,913.00 2,627.10 +0.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 42.06 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-12 31.92 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 20.56 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 123.33 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-12 69.96 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-12 31.39 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 59.51 2,627.10 +0.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 6.00 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-12 4.57 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 4.00 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 14.41 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-12 7.42 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-12 4.80 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 12.43 2,627.10 +0.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-03 0.02 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,627.10 +0.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-03 12.85 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,627.10 +0.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-03 12.85 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,627.10 +0.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,627.10 +0.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,627.10 +0.7%

Syncom Formulations (India) Ltd. FAQ's

What is Syncom Formulations share price?

Can I buy Syncom Formulations shares now?

What is the Market Cap of Syncom Formulations?

What are the key metrics to analyse Syncom Formulations?

What is the 52 Week High and Low of Syncom Formulations?

What is the trend of Syncom Formulations share price?